OTI Presented at Future Ophthalmology Forum
July 11th 2025, OTI has been selected to present at 2025 Future Ophthalmology Forum -Europeon Forum as Private Company Showcase at on September 11, 2025 at Copenhagan, Demark. Prior, OTI has been participating Future Ophthalmology Forum since 2021, and made presentations as Private Company Showcase in 2023 European Forum at Vienna, Austria, and 2024 European Forum at Bacelona, Spain. Video recordings: https://www.ophthalmology-futures.com/past-forums/
Revolutionizing Modern Medicine Development
OTI Participated on FDA Hosted CEO Forum in Boston, Massachusetts
June 17th, 2025, I had the pleasure to attend FDA commissioner hosted CEO Forums in Boston during 2025 BIO Convention, along with ~120 CEOs and executive leaders from Massachussetts and the NE region. My big takehome message from the new administration is FDA's Priorities at big data frontier, FDA encourages biotech Pharma to leverage big data real world evidence for regulatory submission, which helps to reduce costs and accelerate medicine innovation, focusing on curative (doi: 10.1001/jama.2025.10116). At the forum, I had a chance to share my views about the need for increasing the bar for drug efficacy scruitiny at early stage clinical development. Traditionally, as long as a drug is safe, FDA gives a green light. This has to change with increased big data and AI tools. We are very appreciative of this informative and direct dialogues with Dr. Marty A. Makary, M.D., M.P.H and sharing our concerns, feedback and suggestions. OTI's big data strategy is aligned with FDA's real word evidence policy, OTI is a pioneer in leveraging big data to solve the biggest problems - 90% failure in medicine development.
OTI's Founder/CEO
Marquis Who's Who America
Dr. Tina Guanting Qiu, Founder and CEO of Ophthalmic Therapeutic Innovation (OTI), has been recognized in the 2024 edition of Marquis Who’s Who in America, joining a distinguished list of accomplished professionals. She was first honored by Marquis in 2021 for Excellence in Ophthalmology and subsequently received the Albert Nelson Marquis Lifetime Achievement Award and the Marquis Humanitarian Award in 2023. In 2024, Dr. Qiu was named "Top Physician, Entrepreneur & Innovator of the Year" by the International Association of Top Professionals (IAOTP), which further recognized her leadership as the "Empowered Woman of the Year 2025."
A naturalized U.S. citizen, Dr. Qiu has dedicated over 25 years to advancing ophthalmic therapeutic innovation, spanning stem cell transplantation, gene therapy, and drug discovery & medicine innovation. She is accomplished ophthalmic surgeon and stem cell biologist, by pioneering big data, she became the sole inventor of the MMP-based platform therapy for glaucoma—a novel approach targeting IOP normalization via tissue rejuvenation to halt and reverse vision loss. Her work integrates clinical insight, translational science, and big data analytics which is redefining glaucoma specialty care in decades to come.
Dr. Qiu has been selected by International Association of Top Professionals (IAOTP)-2025.
The Great Work of Your Life Interview with Tina Guanting Qiu, MD, Ph.D. EMBA
Dr Qiu Recognized by Marquis Who's Who
Peabody, Massachusetts: Dr Tina Guanting Qiu has been recognized as Excellence in Ophthalmology by Marquis Who's Who in 2021. https://www.24-7pressrelease.com/press-release/483959/dr-tina-guanting-qiu-recognized-by-marquis-whos-who-for-excellence-in-ophthalmology
OTI Established Top Scientific Medical Advisory Board
OTI-2024 - the first in class, best in class MMP Therapy for curing glaucoma blindness.
As OTI is re-introducing Trabodenoson/OTI-2024 as the first in class and first curative therapy for treating refractory glaucoma and glauocmateous neural degeneration, we are honored to have onboarded four world- class scientific medical advisors to help enducate the scientific patient community of MMP based therapeutic platform, featuring OTI-2024 derived MMP therapy, as the first in class and best in class adenosine derived MMP therapy, it is the best in this new therapeutic domain (better than Durysta (One time), iDose (one time) and SLT laser.
1. Repositing Trabodenoson as a new MMP Agent
Dr. James Tsai noted: "Our strategy is to market Trabodenoson not as an IOP lowering drug but as a MMP therapeutic agent with long-term TM benefits with modulation of any IOP fluctuations and less need for consistent adherence to medication use"
2. First in class and best in class Adenosine drug.
TBD
3. IOP Normalization & 24hr IOP Home Monitor
TBD
OTI Pioneer in Big Data for IP Innovation
OTI Patent Update
May 1st 2025. OTI (Massachusetts) announces its 2nd PCT publication: WO2025090106 - COMPOSITIONS AND METHODS FOR TREATING NEURAL DEGENERATION IN GLAUCOMA AND RELATED CONDITIONS. This patent protects the breakthrough discovery of glaucoma disease root cause and matrix metalloproteinase (MMP) platform therapy for treating glaucoma neural degeneration via IOP normalization (new). OTI is creating a new MMP therapeutic market for glaucoma specialty care.
March 10, 2025. OTI (Massachusetts) announces the completion of the first PCT national phase filings with US, EU, Canada, Australia, Japan, China, and India. PCT #1 Pub Number: WO2024030766 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED CONDITIONS.